Supraciliary microstent implantation for open-angle glaucoma: multicentre 3-year outcomes

Area of Science:

• Ophthalmology
• Glaucoma Surgery
• Medical Device Technology

Background:

• Open-angle glaucoma (OAG) is a leading cause of irreversible blindness worldwide.
• Current treatments aim to reduce intraocular pressure (IOP) to prevent optic nerve damage.
• Minimally invasive glaucoma surgeries (MIGS) offer alternatives to traditional procedures.

Purpose of the Study:

• To evaluate the long-term safety and effectiveness of the CyPass supraciliary microstent when implanted alone in OAG patients.
• To assess IOP reduction and medication usage over a 3-year follow-up period.

Main Methods:

• A registry study involving 225 eyes of 178 patients with OAG across 12 European sites.
• CyPass Micro-Stent implantation was performed as a standalone procedure.
• Primary safety outcome was adverse event incidence; secondary outcomes included changes in IOP and medication use.

Main Results:

• Mean baseline IOP was 22.6 ± 6.7 mm Hg, with an average of 2.2 medications per eye.
• Common adverse events included device obstruction (10.2%) and IOP elevation (8.9%).
• Mean IOP reduction ranged from 4.4 to 5.1 mm Hg (15.8%-19.5%) from 6 to 36 months, with significant medication reduction.

Conclusions:

• CyPass microstent implantation is a safe and effective standalone procedure for lowering IOP in OAG patients.
• The device demonstrated sustained IOP reduction and decreased medication dependence for up to 3 years.
• Its safety profile aligns with other MIGS procedures.